Skip to content
10-Q

Quarterly Report

Aprea Therapeutics, Inc. APRE

0001104659-26-059743

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 12.38M sh
Shares Diluted Q1 2026 · Mar 31, 2026 14.69M sh
Shares Diluted Q1 2026 · Mar 31, 2025 5.99M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.76M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.63M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $46.47M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $14.6M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $19.28M
Stockholders Equity Q1 2026 · Mar 31, 2026 $41.59M
Stockholders Equity Q1 2026 · Dec 31, 2025 $12.44M
Stockholders Equity Q1 2026 · Mar 31, 2025 $15.55M
Stockholders Equity Q1 2026 · Dec 31, 2024 $19.31M
Current Liabilities Q1 2026 · Mar 31, 2026 $5.3M
Current Liabilities Q1 2026 · Dec 31, 2025 $2.76M
Current Assets Q1 2026 · Mar 31, 2026 $47.25M
Current Assets Q1 2026 · Dec 31, 2025 $15.56M
Total Assets Q1 2026 · Mar 31, 2026 $47.61M
Total Assets Q1 2026 · Dec 31, 2025 $15.93M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.22
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.66
Eps Basic Q1 2026 · Mar 31, 2026 −$0.22
Eps Basic Q1 2026 · Mar 31, 2025 −$0.66
Sga Expense Q1 2026 · Mar 31, 2026 $1.82M
Sga Expense Q1 2026 · Mar 31, 2025 $1.76M
Net Income Q1 2026 · Mar 31, 2026 −$3.29M
Net Income Q1 2026 · Mar 31, 2025 −$3.93M
Operating Income Q1 2026 · Mar 31, 2026 −$3.43M
Operating Income Q1 2026 · Mar 31, 2025 −$4.09M